What does this research mean for the field?

Major antihypertensive drug classes show no significant difference in overall stroke prevention, as the magnitude of systolic blood pressure reduction is the primary determinant of benefit. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The review aims to systematically compare the effects of different antihypertensive drug classes on stroke prevention.

March 21, 2026CureusOpen Access

Major antihypertensive classes show no difference in stroke prevention, as SBP reduction magnitude drives benefit.

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Hypertension (n=180342). Intervention: Antihypertensive drug classes (ACEIs, ARBs, BBs, CCBs, diuretics) vs. Another antihypertensive drug class or placebo. Primary outcome: Fatal or non-fatal stroke incidence (RR 0.94, 95% CI 0.83-1.05, p=>0.05).

View Full Paper

Ask AI

Bookmark

Why the study?

Whether different classes of antihypertensive drugs provide equal protection against stroke remains controversial.

Does the choice of specific antihypertensive drug class reduce stroke incidence in adults with hypertension?

Population

180,342 participants across 10 RCTs

Comparison

ACEIs, ARBs, BBs, CCBs, or diuretics vs another drug class or placebo

Design

Systematic review and meta-analysis of randomized controlled trials

Key result

Major antihypertensive drug classes showed no significant difference in overall stroke prevention (RR 0.94), as the magnitude of systolic blood pressure reduction was the primary determinant of benefit.

Authors

ZSZobair Ibn ShamsEpsom Hospital KMKazi Iffat Jahan MayaDhaka Medical College and Hospital SSSyed Tasin Bin ShahidEpsom Hospital

Discussion

Member takes

Overview

Prioritize SBP reduction over antihypertensive class for stroke prevention; reinforces BP lowering magnitude as the primary determinant.

Key Points

The review aims to systematically compare the effects of different antihypertensive drug classes on stroke prevention.
Conducted a systematic review following PRISMA guidelines.
Analyzed randomized controlled trials published since January 2000.
Compared different antihypertensive classes including ACEIs, ARBs, BBs, CCBs, and diuretics.
Used random-effects model for data pooling and conducted subgroup analyses.
No significant difference in stroke risk among drug classes with RR: 0.94; 95% CI: 0.83-1.05.
Substantial heterogeneity in results (I²=65%).
Moderate SBP differences (>2 mmHg) led to a significant stroke risk reduction (RR: 0.78; 95% CI: 0.71-0.85).
Minimal SBP differences (<2 mmHg) did not affect stroke risk (RR: 1.02; 95% CI: 0.90-1.14).
Overall, no drug class was superior for stroke prevention.

Study Design

Type

Meta-Analysis (n=180,342)

Structured PICO

Does the choice of specific antihypertensive drug class reduce stroke incidence in adults with hypertension?

Population

Adults with diagnosed primary hypertension or a history of cerebrovascular event/TIA

Intervention

Antihypertensive drug classes (ACEIs, ARBs, beta-blockers, CCBs, or diuretics)

Comparator

Another antihypertensive drug class or placebo

Outcome

Stroke incidence (fatal and non-fatal)hard clinical

Main Result

Effect estimate: RR 0.94 (95% CI 0.83-1.05)

p-value: p=>0.05

The magnitude of achieved systolic blood pressure reduction, rather than the specific antihypertensive drug class used, is the primary determinant of stroke prevention in hypertensive patients.

Limitations

Considerable clinical and methodological heterogeneity among the included studies
Potential performance bias from PROBE designs or treatment strategy trials
Inclusion of fixed-dose combinations may confound the effect of a single drug class
Ecological fallacy risk due to reliance on study-level aggregate data for SBP differences
Inability to perform time-to-event analyses or adjust for patient-level covariates due to lack of individual patient data
Inability to analyze stroke outcomes by pathological subtype (ischemic vs. hemorrhagic)
Restriction to English-language publications
Substantial heterogeneity among included studies (I²=65%)
Risk of performance bias due to the inclusion of open-label or strategy trials

Cite This Study

Shams et al. (2026) conducted a meta-analysis in Hypertension (n=180,342). Antihypertensive drug classes (ACEIs, ARBs, BBs, CCBs, diuretics) vs. Another antihypertensive drug class or placebo was evaluated on Fatal or non-fatal stroke incidence (RR 0.94, 95% CI 0.83-1.05, p=>0.05). Major antihypertensive drug classes showed no significant difference in overall stroke prevention (RR 0.94), as the magnitude of systolic blood pressure reduction was the primary determinant of benefit.

synapsesocial.com/papers/69be35a96e48c4981c67412d https://doi.org/10.7759/cureus.105452

View Full Paper

Ask AI

Bookmark

March 21, 2026CureusOpen Access

Major antihypertensive classes show no difference in stroke prevention, as SBP reduction magnitude drives benefit.

View Full Paper

Ask AI

Bookmark

Why the study?

Whether different classes of antihypertensive drugs provide equal protection against stroke remains controversial.

Does the choice of specific antihypertensive drug class reduce stroke incidence in adults with hypertension?

Population

180,342 participants across 10 RCTs

Comparison

ACEIs, ARBs, BBs, CCBs, or diuretics vs another drug class or placebo

Design

Systematic review and meta-analysis of randomized controlled trials

Key result

Authors

ZSZobair Ibn ShamsEpsom Hospital KMKazi Iffat Jahan MayaDhaka Medical College and Hospital SSSyed Tasin Bin ShahidEpsom Hospital

Discussion

Member takes

Overview

Prioritize SBP reduction over antihypertensive class for stroke prevention; reinforces BP lowering magnitude as the primary determinant.

Key Points

The review aims to systematically compare the effects of different antihypertensive drug classes on stroke prevention.
Conducted a systematic review following PRISMA guidelines.
Analyzed randomized controlled trials published since January 2000.
Compared different antihypertensive classes including ACEIs, ARBs, BBs, CCBs, and diuretics.
Used random-effects model for data pooling and conducted subgroup analyses.
No significant difference in stroke risk among drug classes with RR: 0.94; 95% CI: 0.83-1.05.
Substantial heterogeneity in results (I²=65%).
Moderate SBP differences (>2 mmHg) led to a significant stroke risk reduction (RR: 0.78; 95% CI: 0.71-0.85).
Minimal SBP differences (<2 mmHg) did not affect stroke risk (RR: 1.02; 95% CI: 0.90-1.14).
Overall, no drug class was superior for stroke prevention.

Study Design

Type

Meta-Analysis (n=180,342)

Structured PICO

Does the choice of specific antihypertensive drug class reduce stroke incidence in adults with hypertension?

Population

Adults with diagnosed primary hypertension or a history of cerebrovascular event/TIA

Intervention

Antihypertensive drug classes (ACEIs, ARBs, beta-blockers, CCBs, or diuretics)

Comparator

Another antihypertensive drug class or placebo

Outcome

Stroke incidence (fatal and non-fatal)hard clinical

Main Result

Effect estimate: RR 0.94 (95% CI 0.83-1.05)

p-value: p=>0.05

The magnitude of achieved systolic blood pressure reduction, rather than the specific antihypertensive drug class used, is the primary determinant of stroke prevention in hypertensive patients.

Limitations

Considerable clinical and methodological heterogeneity among the included studies
Potential performance bias from PROBE designs or treatment strategy trials
Inclusion of fixed-dose combinations may confound the effect of a single drug class
Ecological fallacy risk due to reliance on study-level aggregate data for SBP differences
Inability to perform time-to-event analyses or adjust for patient-level covariates due to lack of individual patient data
Inability to analyze stroke outcomes by pathological subtype (ischemic vs. hemorrhagic)
Restriction to English-language publications
Substantial heterogeneity among included studies (I²=65%)
Risk of performance bias due to the inclusion of open-label or strategy trials

Cite This Study

synapsesocial.com/papers/69be35a96e48c4981c67412d https://doi.org/10.7759/cureus.105452

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark